Evidence

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

September 1, 2019

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue 5, Pages 808–823. AUTHORS: Lorenza Mittempergher, Leonie J.M.J. Delahaye, Anke T. Witteveen, Jacob B. Spangler, Fariet Hassenmahomed, Sammy Mee, Soufiane Mahmoudi, Jiang Chen, Simon Bao, Mireille H.J. Snel, Sandra Leidelmeijer, Naomi Besseling, Anne Bergstrom Lucas, Carlos Pabón-Peña, Sabine C. Linn, Christa Dreezen, Diederik Wehkamp, Bob Y. Chan,…

Read more

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

April 18, 2019

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). AUTHORS: Floris H. Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch, William Audeh, Winand N. M. Dinjens, Rene Bernards & Pat Whitworth ABSTRACT: Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classified clinically as Luminal-type. We showed previously that molecular subtyping using the 80-gene signature (80-GS) reclassified a…

Read more

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

March 27, 2019

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Science. AUTHORS: Kathleen A. Grant; Ettienne J. Myburgh; Elizabeth Murray; Fredrieka M. Pienaar; Martin Kidd; Colleen A. Wright; Maritha J. Kotze SUMMARY: Neither single-gene genomic mRNA nor IHC reporting of ER and PR status can replace the combined use of MammaPrint/BluePrint genomic molecular subtyping. -128 patients. Read more:…

Read more

AACR BluePrint HER2 Poster 2612

April 18, 2018

AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, ISPY2 TRIAL Investigators, Laura Esserman and Laura van ‘t Veer DESCRIPTION: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY2 breast cancer patients BluePrint® molecular profile determines the mRNA levels of 80…

Read more

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

September 22, 2017

PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep 22, 2017. https://doi.org/10.4048/jbc.2017.20.3.246 AUTHORS: Areej Fatima, Fomaz Tariq, Muhammad Faraz Arshad Malik, Muhammad Qasim, and Farhan Haq SUMMARY: DNA copy number variations (CNVs) in realtion to MammaPrint 70-genes (cell line and TCGA data). Read more: Copy Number Profiling of MammaPrint…_Fatima et al_Journal of Breast Cancer 2017  

Read more

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

April 26, 2017

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Beitsch, MD; Pat Whitworth, MD; Paul Baron, MD; Michael C. Rotkis, MD; Angela M. Mislowsky, MD; Paul D. Richards, MD; Mary K. Murray, MD; James V. Pellicane, MD; Carrie L. Dul, MD; Charles H. Nash, MD; Lisette Stork-Sloots, MSc; Femke de Snoo, MD, PhD; Sarah Untch, BS;…

Read more

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

October 21, 2016

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue 3; pp 669–675. AUTHORS: Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V. Pellicane, Charles Nash, Mary Murray, Laura A. Lee, Carrie L. Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A. de Snoo, Jennifer Beatty ABSTRACT: Hormone receptor-positive (HR+) tumors have heterogeneous biology and present a challenge for…

Read more

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

July 6, 2016

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder, Mark Gittleman, NBRST Investigators Group SUMMARY: This substudy showed that NAT significantly altered the genomic signature of the patient’s breast cancer compared with the patient’s pre-treatment genomic profile. These alterations occurred in a subtype-dependent manner, suggesting that…

Read more

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

May 1, 2016

PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Baron, Peter Beitsch, Danielle Boselli, James Symanowski, James V. Pellicane, Jennifer Beatty, Paul Richards, Angela Mislowsky, Charles Nash, Laura A. Lee, Mary Murray, Femke A. de Snoo, Lisette Stork-Sloots, Mark Gittleman, Stephanie Akbari, Pat Whitworth SUMMARY: We found that although size was correlated inversely with the frequency of…

Read more

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

November 1, 2015

PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Katharine Yao, Robert Goldschmidt, Mary TurkJelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli SUMMARY: Retrospective, observational study comparing MP+BP subtyping with long-term outcomes: MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4), while MammaPrint high-risk patients had a 10-year DMFS of 87%. Read…

Read more

Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy

September 4, 2014

PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Melanie Royce, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück SUMMARY: The overall pCR plus npCR rate was 25 % (30/122). Stratified by BluePrint/MammaPrint, patients of HER2 type had the best response (59 %), while luminal A (7 %) and B (9 %) subtypes had the poorest. The pCR…

Read more

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

August 7, 2014

PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue 10; pp 3261–3267. AUTHORS: Pat Whitworth, MD; Lisette Stork-Sloots, MSc; Femke A. de Snoo, MD, PhD; Paul Richards, MD; Michael Rotkis, MD; Jennifer Beatty, DO; Angela Mislowsky, MD; James V. Pellicane, MD; Bichlien Nguyen, MD; Laura Lee, MD; Charles Nash, MD; Mark Gittleman, MD; Stephanie Akbari, MD;…

Read more

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

August 4, 2013

PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Floris H. Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards ABSTRACT: It is well established that only estrogen receptor (ER)-positive tumors benefit from hormonal therapies. We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor α (ERα), but fails to respond to hormonal therapy due…

Read more

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

June 12, 2013

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Glück S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. ABSTRACT: The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in patients with early-stage breast cancer using BluePrint and…

Read more

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

August 15, 2012

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug 15. AUTHORS: Nguyen B., Cusumano P.G., Deck K., Kerlin D., Garcia A.A., Barone J..L, Rivera E., Yao K., de Snoo F.A., van den Akker J., Stork-Sloots L., Generali D. SUMMARY: The concordance between BluePrint and IHC/FISH subtyping was 94% for the Luminal-type, 95% for the HER2-type, and…

Read more

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

May 1, 2012

PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Oscar Krijgsman, Paul Roepman, Wilbert Zwart, Jason S. Carroll, Sun Tian, Femke A. de Snoo, Richard A. Bender, Rene Bernards, Annuska M. Glas SUMMARY: BluePrint classification of a patient cohort that was treated with neoadjuvant chemotherapy (n = 133) shows improved distribution of pathological Complete Response (pCR), among…

Read more